What Novadip Biosciences does

Novadip Biosciences is a clinical-stage Belgian biotech founded in 2013 as a spin-off from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of Prof. Dr. Denis Dufrane. The company operates from a 45-person headquarters in Mont-Saint-Guibert, Belgium, and is publicly and privately funded through institutional life-sciences investors (New Science Ventures, CRCP Lifescience Fund, SRIW, VIVES, Fund+, China Resources) and a €18M EIB venture debt facility, with cumulative funding of approximately €88M and a €50M Series C in preparation.

The company's core asset is the proprietary 3M3 tissue regeneration platform — a three-dimensional, scaffold-free extracellular matrix seeded with differentiated adipose-derived stem cells (ASCs) that generate growth factors and miRNAs to mimic the physiology of natural healing. The platform has been extended into three product classes: 3MAUTO (autologous ASC products), 3MALLO (off-the-shelf lyophilised allogeneic matrix products), and 3MEXO (cell-free miRNA/exosome products). Lead clinical asset NVD-003 is a moldable, autologous, large-volume cellular graft currently in a Phase 3 pivotal trial for congenital pseudarthrosis of the tibia (CPT), with FDA Orphan Drug, Rare Pediatric Disease, Fast Track, and RMAT designations, plus Priority Review Voucher eligibility worth more than $100M on approval. Allogeneic lead NVD-X3 is a lyophilised, off-the-shelf bone graft in a Phase 2b/3 study for 2-level cervical spine fusion after FDA IND clearance in November 2024. Preclinical pipeline includes NVD-M2 (matrisphere microRNA delivery for solid tumors) and 3MEXO for oncology and tissue rejuvenation.

Novadip is pre-commercial. Current revenue streams are non-existent; cash flow comes from dilutive and non-dilutive funding rather than product sales. The commercial model will operate on two distinct revenue mechanics: per-patient autologous product charges for NVD-003 (planned launch 2027 in pediatric CPT and 2029 in adult non-union) and broad distribution of the off-the-shelf NVD-X3 product through standard medical supply chains post-approval. Manufacturing takes place at a GMP-certified facility in Belgium with a global supply chain platform, and the company has begun building US commercial readiness around a US Phase 3 trial footprint and senior leadership additions (CTO Neil Johnson, CFO Soumya Chandramouli).

Name

Novadip Biosciences

Legal name

NOVADIP Biosciences S.A.

Website

http://www.novadip.com/

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Novadip Biosciences is a Belgian clinical-stage biotech developing the 3M3 tissue regeneration platform, using adipose-derived stem cells in a 3D extracellular matrix to produce autologous (NVD-003) and allogeneic (NVD-X3) bone grafts for pediatric CPT, bone non-union, and spinal fusion.

Ownership category

akta.pro rank

Product category

Regenerative Medicine - Bone Tissue Engineering

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Regenerative medicine
• Tissue engineering
• Cell therapy
• Bone regeneration
• Stem cell therapy

Headquarters

HQ city

Mont-saint-guibert

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Autologous Cell Therapy Products (NVD-003): Revenue from sale of patient-specific autologous cell therapy products derived from patient's own adipose stem cells. Products manufactured per patient for specific clinical indications including congenital pseudarthrosis of the tibia and bone non-union. Market launch planned for 2027 for pediatric CPT indication.
2. Allogeneic Bone Graft Products (NVD-X3): Revenue from off-the-shelf allogeneic bone grafting materials for spinal fusion and trauma applications. Lyophilized product stored at room temperature for broad distribution. Phase 2b/3 trial targeting cervical spine fusion with market entry planned post-approval.
3. FDA Priority Review Voucher: Non-dilutive funding opportunity worth over $100 million upon FDA approval of NVD-003 for congenital pseudarthrosis of the tibia. Eligible through Rare Pediatric Disease designation and Priority Review Voucher program.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Novadip Biosciences develops and manufactures autologous and allogeneic regenerative tissue products based on its proprietary 3M3 platform, which uses 3-dimensional scaffold-free extracellular matrices with adipose-derived stem cells. Its lead products are NVD-003, a personalized autologous cell therapy for congenital pseudarthrosis of the tibia and bone non-union (currently in Phase 3), and NVD-X3, an off-the-shelf lyophilized allogeneic bone graft for spinal fusion and trauma applications (in Phase 2b/3).

Product overview

Novadip Biosciences develops a portfolio of regenerative tissue products based on its proprietary 3M3 technology platform, which uses 3-dimensional adipose-derived stem cell matrices to deliver growth factors and miRNAs for bone and tissue regeneration. The core products include NVD-003 (autologous therapy for congenital pseudarthrosis of the tibia and bone non-union) and NVD-X3 (allogeneic off-the-shelf bone graft for spinal fusion and trauma). Preclinical programs include NVD-M2 for solid tumors and 3MEXO exosome products for oncology and tissue rejuvenation.

Differentiator

Problem solved

Functional benefit

Brands

• 3M3 Platform: 3M3 tissue regeneration technology platform using adipose-derived stem cells within a three-dimensional extracellular matrix for bone and tissue regeneration
• 3MAUTO
• 3MALLO
• 3MEXO

Products and services

• NVD-003 Autologous adipose-derived stem cell therapy for critical size bone reconstruction. A 3D osteogenic graft derived from a patient's own adipose stem cells combined with hydroxyapatite/beta-tricalcium phosphate particles, designed for single-treatment bone union in congenital pseudarthrosis of the tibia (CPT) and bone non-union.
• NVD-X3 Allogeneic 'off-the-shelf' bone grafting material created from human osteogenic adipose tissue-derived mesenchymal stem cells. Lyophilized powder implant for accelerated bone healing in spinal fusion, trauma, and bone non-union patients with comorbidities.
• 3MEXO (Exosomes) Allogeneic exosome product program for oncology and skin/tissue rejuvenation. Generates highly specific and reproducible cell-free miRNAs/exosomes for tissue regeneration following surgical resection, with potential anti-cancer activity.
• NVD-M2 Allogeneic preclinical asset utilizing microRNA and proteins delivered via a matrisphere to treat solid tumors and metastatic cancers.

Quantifiable outcome

• 88% efficacy across all patients (n=17) treated with NVD003 to date - 100% efficacy when mechanical stability of fracture is achieved
• +5 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• MytoscoreTechnology or Integration · 4 September 2025Strategic manufacturing partnership with Mytos, a London-based biotechnology company automating cell manufacturing, to integrate its iDEM automated platform for cell therapy production. Partnership aims to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.
• StemSightcoreTechnology or Integration · 4 September 2025Manufacturing collaboration with StemSight as part of Mytos partnership to power next-generation cell therapy trials. Focus on integrating automated manufacturing across diverse therapeutic applications including ocular diseases and bone regeneration.
• Rinri TherapeuticscoreTechnology or Integration · 4 September 2025Manufacturing collaboration with Rinri Therapeutics as part of Mytos partnership network. Partnership integrates automated cell manufacturing across therapeutic applications including hearing loss and bone regeneration.
• Andrew Lloyd AssociatescoreGTM or Marketing Partner · 12 December 2024Partnership with Andrew Lloyd Associates over the past 12 months focusing on public relations and communications for treatments addressing critical size bone defects. Andrew Lloyd Associates handles media relations, press release distribution, and analyst contacts for Novadip.
• Cliniques universitaires Saint-LuccoreStrategic or Co-development Partner · 1 January 2018Long-standing clinical partnership with Cliniques universitaires Saint-Luc (UCLouvain academic hospital) for compassionate use programs and clinical trials of NVD003 in congenital pseudarthrosis of the tibia. Professor Pierre-Louis Docquier serves as coordinating investigator. Four pediatric patients treated under compassionate use with successful outcomes at 4-7 year follow-up.
• Université Catholique de Louvain (UCLouvain)coreStrategic or Co-development PartnerSpin-off company from Université Catholique de Louvain and St. Luc University Hospital based on scientific discoveries of founder Prof. Dr. Denis Dufrane. Supported by Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.
• St. Luc University HospitalcoreStrategic or Co-development PartnerFounding partner institution and spin-off origin for Novadip. Research collaboration with musculoskeletal tissue bank and tissue/cells therapy center.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic (Spine & Biologics): Largest spine medical device player, with INFUSE Bone Graft (rhBMP-2) and other orthobiologics for spinal fusion. Dominant incumbent that NVD-X3 must displace in the bone graft market.
• Bioventus: Established orthobiologics company with bone graft substitutes (Osteoamp, Exponent) and ultrasonic bone healing systems for spine fusion and trauma. Direct competitor in the bone graft substitute market that NVD-X3 is targeting.
• Stryker: Major medical device company with broad orthobiologics and spine portfolio (formerly Wright Medical, acquired). Comparable as a large incumbent with significant bone graft and spine fusion product lines competing in NVD-X3's target market.
• Orthofix Medical: Global orthopedic and spine medical device company with bone growth stimulators, orthobiologics, and motion preservation products. Comparable as a broader orthopedic/regenerative medicine incumbent with overlapping products in bone healing.

Emerging players

• Capricor Therapeutics: Clinical-stage biotechnology company developing cell-derived exosome and cell therapy products. Comparable emerging cell therapy peer with exosome platform overlap to Novadip's 3MEXO program.
• Histogenics (now Ocugen/Oligogen): Earlier peer in regenerative cartilage and orthopedic cell therapy (formerly NeoCart). Comparable as an emerging cell therapy developer targeting orthopedic and musculoskeletal regeneration with autologous platforms.
• Bone Biologics: Clinical-stage orthobiologics company developing recombinant protein-based bone graft substitutes for spinal fusion. Emerging peer in the same bone regeneration therapeutic category with similar regulatory pathway.

Direct peers

• Xtant Medical: Pure-play orthobiologics company focused on spinal fusion and bone graft substitute products. Direct peer in bone graft market for trauma and spine fusion indications that Novadip's NVD-X3 targets.
• Vericel: Commercial cell therapy company with MACI (autologous cartilage repair) and Epicel (burn treatment). Closely comparable to Novadip as an orthopedic cell therapy developer with FDA-approved autologous products and similar commercialization pathway through specialty surgeons.
• Mesoblast: Commercial-stage regenerative medicine company developing mesenchymal stem cell therapies for orthopedic indications including discogenic back pain and acute graft-versus-host disease. Most directly comparable cell-therapy peer targeting orthopedic bone and spine applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/novadip-biosciences-s-a-

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novadip Biosciences